Check-Cap (NASDAQ:CHEK) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

CHEK stock opened at $1.42 on Wednesday. Check-Cap has a one year low of $1.13 and a one year high of $3.94. The firm’s fifty day moving average is $1.70 and its 200 day moving average is $2.02. The firm has a market cap of $8.31 million, a PE ratio of -0.47 and a beta of 0.36.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.